Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Baxter
Express Scripts
Cipla
Healthtrust
Farmers Insurance
QuintilesIMS
McKesson
Cantor Fitzgerald

Generated: April 24, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,432,932

« Back to Dashboard

Summary for Patent: 6,432,932
Title: Method for inhibiting bone resorption
Abstract:Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Inventor(s): Daifotis; Anastasia G. (Westfield, NJ), Santora, II; Arthur C. (Watchung, NJ), Yates; A. John (Westfield, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/388,659
Patent Claims: 1. A method for treating or preventing osteoporosis in a mammal, said method comprising orally administering to said mammal a pharmaceutically effective amount of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof as a unit dosage according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.

2. A method according to claim 1 wherein said mammal is a human.

3. A method according to claim 2 wherein said dosing interval is once-weekly.

4. A method according to claim 3 wherein said unit dosage comprises from about 3.5 mg to about 200 mg, on an acid active basis, of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.

5. A method according to claim 4 wherein said pharmaceutically acceptable salt is risedronate monosodium hemi-pentahydrate.

6. A method according to claim 4 wherein said unit dosage comprises about 35 mg, on an acid active basis, of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.

7. A method according to claim 4 wherein said unit dosage comprises about 40 mg, on an acid active basis, of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.

8. A method according to claim 4 wherein said unit dosage comprises about 45 mg, on an acid active basis, of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.

9. A method according to claim 4 wherein said unit dosage comprises about 50 mg, on an acid active basis, of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.

10. A method according to claim 6 wherein said pharmaceutically acceptable salt is risedronate monosodium hemi-pentahydrate.

11. A method according to claim 7 wherein said pharmaceutically acceptable salt is risedronate monosodium hemi-pentahydrate.

12. A method according to claim 8 wherein said pharmaceutically acceptable salt is risedronate monosodium hemi-pentahydrate.

13. A method according to claim 9 wherein said pharmaceutically acceptable salt is risedronate monosodium hemi-pentahydrate.

14. A method according to claim 3 wherein said unit dosage comprises about 1.5 to about 6000 .mu.g/kg body weight of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.

15. A method according to claim 3 wherein said unit dosage comprises about 10 to about 2000 .mu.g/kg body weight of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.

16. A method according to claim 14 wherein said pharmaceutically acceptable salt is risedronate monosodium hemi-pentahydrate.

17. A method according to claim 15 wherein said pharmaceutically acceptable salt is risedronate monosodium hemi-pentahydrate.

18. A method according to any one of claims 1-17 wherein said unit dosage is in the form of a tablet.

19. A method according to any one of claims 1-17 wherein said unit dosage is in the form of a capsule.

20. A method according to any one of claims 1-17 wherein said unit dosage is in the form of a liquid.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fuji
Deloitte
UBS
Daiichi Sankyo
Fish and Richardson
Citi
AstraZeneca
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.